CNSX:SNN Smith & Nephew (SNN) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free SNN Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume44,398 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Smith & Nephew alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Smith & Nephew Stock (CNSX:SNN)Sunniva Inc., a vertically integrated cannabis company, focuses on the cultivation, production, and distribution of various therapeutic solutions in Canada and the United States. The company operates through Patient Counselling, Merchandising, and Cultivation & Extraction segments. It offers its products under the Sun Fire, Kyndness, and Herbella brands. The company was formerly known as Sunniva Holdings Corp. and changed its name to Sunniva Inc. in August 2017. Sunniva Inc. was founded in 2014 and is headquartered in Vancouver, Canada.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> SNN Stock News HeadlinesApril 3, 2024 | finance.yahoo.comInvestors five-year losses continue as Smith & Nephew (LON:SN.) dips a further 5.6% this week, earnings continue to declineApril 1, 2024 | finance.yahoo.comSmith & Nephew PLC's Dividend AnalysisApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 12, 2024 | benzinga.comBritish MedTech Firm Smith & Nephew Seeks To Adopt US-Inspired Pay Policy to Navigate Shareholder SkepticismMarch 11, 2024 | thetimes.co.ukSmith & Nephew plans pay rise for US bossesMarch 11, 2024 | ft.comSmith & Nephew seeks pay premium for US executives over those in UKMarch 1, 2024 | finance.yahoo.comSmith & Nephew plc Just Missed EPS By 38%: Here's What Analysts Think Will Happen NextFebruary 28, 2024 | markets.businessinsider.comBalanced Outlook: Hold Rating Justified for Smith & Nephew Amidst Growth and Market ChallengesApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 28, 2024 | finance.yahoo.comSmith & Nephew plc (NYSE:SNN) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comSmith+Nephew and U.S. Army Institute of Surgical Research to engage in Master Cooperative Research and Development AgreementFebruary 28, 2024 | msn.comSmith & Nephew eyes stronger margins as orthopaedics demand drives profits to £764mFebruary 27, 2024 | markets.businessinsider.comSmith & Nephew FY Trading Profit Rises; Revenue Up 7.2% On Underlying BasisFebruary 13, 2024 | finance.yahoo.comSmith+Nephew announces commercial launch of its AETOS™ Shoulder System for anatomic and reverse shoulder replacement at AAOS 2024 Annual MeetingFebruary 12, 2024 | finanznachrichten.deSmith & Nephew UK Ltd: Smith+Nephew unveils expanded Sports Medicine portfolio to enable biological healing at AAOS 2024 Annual MeetingFebruary 12, 2024 | finance.yahoo.comSmith+Nephew unveils expanded Sports Medicine portfolio to enable biological healing at AAOS 2024 Annual MeetingJanuary 23, 2024 | finance.yahoo.comSmith & Nephew plc's (LON:SN.) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?January 14, 2024 | finance.yahoo.comAustralia’s approach to musculoskeletal injury care and reimbursement demands rethink: ReportDecember 28, 2023 | seekingalpha.comSmith & Nephew: Orthopedics Growth Continues To Drive Sales ForwardNovember 29, 2023 | finance.yahoo.comIs Smith & Nephew plc (LON:SN.) Trading At A 40% Discount?November 22, 2023 | lse.co.ukSmith & Nephew buys sports medicine firm focused on knee repairNovember 22, 2023 | markets.businessinsider.comSmith+Nephew To Buy Agili-C Developer CartiHeal In Up To $330 Mln DealOctober 13, 2023 | msn.comSmith & Nephew: Exorbitant NWC Requirements To Maintain Competitive PositionOctober 11, 2023 | finanznachrichten.deSmith & Nephew plc: Smith+Nephew opens new state-of-the-art surgical innovation and training centre in the heart of MunichOctober 4, 2023 | bizjournals.comMLGW in talks to purchase Smith & Nephew facility for HQ move from Downtown to CordovaOctober 3, 2023 | finance.yahoo.comThe Zacks Analyst Blog Highlights Abbott Laboratories, Koninklijke Philips and Smith & NephewOctober 2, 2023 | msn.comWhy Ocado, Smith & Nephew, and Diageo shares fell in SeptemberSee More Headlines Receive SNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCNSX SectorMedical Industry Drug Manufacturers—Specialty & Generic Sub-IndustryN/A Current SymbolCNSX:SNN CUSIPN/A CIKN/A Webwww.sunniva.com Phone1-866-SUNNIVAFaxN/AEmployees18,581Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Anthony F. Holler M.D. (Age 71)Co-founder, CEO & Chairman Comp: $340.63kDr. Mark Hamish Kimmins (Age 56)Pres of NHS Comp: $4.68MMr. David WeinmannGlobal Controller & Interim CFORob KnowlesVP of Corp. Devel.Mr. Jose CalderonHead of GrowerKey CompetitorsDigicann VenturesCSE:DCNN45525 (CUR.TO)TSE:CURAbattis BioceuticalsCNSX:ATTAgraflora Organics InternationalCNSX:AGRAAmplify Alternative Harvest ETFCNSX:MJView All Competitors SNN Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Smith & Nephew own? Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Canopy Growth (WEED), Energous (WATT), Cronos Group (CRON), Aurora Cannabis (ACB), CanniMed Therapeutics (CMED), CannTrust (CTST), CannaRoyalty (CNNRF) and Innovative Industrial Properties (IIPR). How do I buy shares of Smith & Nephew? Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (CNSX:SNN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Smith & Nephew plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
